Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.
Pasello G, Fabricio ASC, Del Bianco P, Salizzato V, Favaretto A, Piccin L, Zustovich F, Fabozzi A, De Rossi C, Pigozzo J, De Nuzzo M, Cappelletto E, Bonanno L, Palleschi D, De Salvo GL, Guarneri V, Gion M, Chiarion-Sileni V. Pasello G, et al. Among authors: de salvo gl. J Transl Med. 2024 Mar 5;22(1):242. doi: 10.1186/s12967-024-04920-6. J Transl Med. 2024. PMID: 38443899 Free PMC article.
LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab.
Bonanno L, De Paoli A, Zulato E, Esposito G, Calabrese F, Favaretto A, Santo A, Conte AD, Chilosi M, Oniga F, Sozzi G, Moro M, Ciccarese F, Nardo G, Bertorelle R, Candiotto C, De Salvo GL, Amadori A, Conte P, Indraccolo S. Bonanno L, et al. Among authors: de salvo gl, de paoli a. Clin Cancer Res. 2017 Jul 1;23(13):3316-3324. doi: 10.1158/1078-0432.CCR-16-2410. Epub 2017 Jan 24. Clin Cancer Res. 2017. PMID: 28119362 Clinical Trial.
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies.
Miglietta F, Dieci MV, Giarratano T, Torri V, Giuliano M, Zustovich F, Mion M, Tondini CA, De Rossi C, Bria E, Franchi M, Merlini L, Giannatiempo R, Russo D, Fotia V, Poletti P, Caremoli ER, Arpino MG, De Salvo GL, Zambelli A, Guarneri V. Miglietta F, et al. Among authors: de salvo gl. Eur J Cancer. 2023 Dec;195:113399. doi: 10.1016/j.ejca.2023.113399. Epub 2023 Oct 26. Eur J Cancer. 2023. PMID: 37950941 Free article.
Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients.
Chiarion-Sileni V, Del Bianco P, De Salvo GL, Lo Re G, Romanini A, Labianca R, Nortilli R, Corgna E, Dalla Palma M, Lo Presti G, Ridolfi R; Italian Melanoma Intergroup (IMI). Chiarion-Sileni V, et al. Among authors: de salvo gl. Eur J Cancer. 2003 Jul;39(11):1577-85. doi: 10.1016/s0959-8049(03)00372-1. Eur J Cancer. 2003. PMID: 12855265 Clinical Trial.
Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
Chiarion-Sileni V, Guida M, Ridolfi L, Romanini A, Del Bianco P, Pigozzo J, Brugnara S, Colucci G, Ridolfi R, De Salvo GL; Italian Melanoma Intergroup (IMI). Chiarion-Sileni V, et al. Among authors: de salvo gl. Br J Cancer. 2011 Jun 7;104(12):1816-21. doi: 10.1038/bjc.2011.178. Epub 2011 May 24. Br J Cancer. 2011. PMID: 21610711 Free PMC article. Clinical Trial.
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV, Guarneri V, Zustovich F, Mion M, Morandi P, Bria E, Merlini L, Bullian P, Oliani C, Gori S, Giarratano T, Orvieto E, Griguolo G, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P; Veneto Oncology Network. Dieci MV, et al. Among authors: de salvo gl. Oncologist. 2019 Nov;24(11):1424-1431. doi: 10.1634/theoncologist.2019-0103. Epub 2019 May 31. Oncologist. 2019. PMID: 31152079 Free PMC article.
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
Dieci MV, Guarneri V, Giarratano T, Mion M, Tortora G, De Rossi C, Gori S, Oliani C, Merlini L, Pasini F, Bonciarelli G, Griguolo G, Orvieto E, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P. Dieci MV, et al. Among authors: de rossi c, de salvo gl. Oncologist. 2018 Mar;23(3):297-305. doi: 10.1634/theoncologist.2017-0322. Epub 2017 Nov 13. Oncologist. 2018. PMID: 29133514 Free PMC article.
Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874].
Chiarion-Sileni V, Del Bianco P, Romanini A, Guida M, Paccagnella A, Dalla Palma M, Naglieri E, Ridolfi R, Silvestri B, Michiara M, De Salvo GL. Chiarion-Sileni V, et al. Among authors: de salvo gl. BMC Cancer. 2006 Feb 27;6:44. doi: 10.1186/1471-2407-6-44. BMC Cancer. 2006. PMID: 16504154 Free PMC article. Clinical Trial.
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial.
Guarneri V, Giorgi CA, Cinieri S, Bengala C, Mariani G, Bisagni G, Frassoldati A, Zamagni C, De Rossi C, Amoroso V, Andreetta C, Ferro A, Zambelli A, Gori S, Garrone O, Dieci MV, Orlando L, Pastina I, Beninato T, Moretti G, Genovesi E, Cinefra M, Vicini R, Magni G, De Salvo GL, Conte P. Guarneri V, et al. Among authors: de rossi c, de salvo gl. Eur J Cancer. 2021 Sep;154:21-29. doi: 10.1016/j.ejca.2021.05.008. Epub 2021 Jul 2. Eur J Cancer. 2021. PMID: 34225066 Free article. Clinical Trial.
122 results